关注
Bernhard Ultsch
Bernhard Ultsch
Moderna
在 modernatx.com 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Epidemic profile of Shiga-toxin–producing Escherichia coli O104: H4 outbreak in Germany
C Frank, D Werber, JP Cramer, M Askar, M Faber, M an der Heiden, ...
New England Journal of Medicine 365 (19), 1771-1780, 2011
14652011
Large and ongoing outbreak of haemolytic uraemic syndrome, Germany, May 2011
C Frank, MS Faber, M Askar, H Bernard, A Fruth, A Gilsdorf, M Höhle, ...
Eurosurveillance 16 (21), 19878, 2011
2302011
Herpes zoster in Germany: quantifying the burden of disease
B Ultsch, A Siedler, T Rieck, T Reinhold, G Krause, O Wichmann
BMC infectious diseases 11, 1-8, 2011
1482011
Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community
B Ultsch, O Damm, P Beutels, J Bilcke, B Brüggenjürgen, A Gerber-Grote, ...
Pharmacoeconomics 34, 227-244, 2016
1252016
Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany
B Ultsch, I Köster, T Reinhold, A Siedler, G Krause, A Icks, I Schubert, ...
The European Journal of Health Economics 14, 1015-1026, 2013
962013
A systematic review of the health economic consequences of quadrivalent influenza vaccination
PT de Boer, BM van Maanen, O Damm, B Ultsch, FCK Dolk, P Crépey, ...
Expert review of pharmacoeconomics & outcomes research 17 (3), 249-265, 2017
662017
Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries
O Damm, B Ultsch, J Horn, RT Mikolajczyk, W Greiner, O Wichmann
BMC Public Health 15, 1-19, 2015
542015
Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany
B Ultsch, F Weidemann, T Reinhold, A Siedler, G Krause, O Wichmann
BMC health services research 13, 1-18, 2013
532013
Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero® to reduce meningococcal group B disease in Germany
H Christensen, T Irving, J Koch, CL Trotter, B Ultsch, F Weidemann, ...
Vaccine 34 (29), 3412-3419, 2016
522016
Cost-effectiveness of human papillomavirus vaccination in Germany
O Damm, J Horn, RT Mikolajczyk, MEE Kretzschmar, AM Kaufmann, ...
Cost Effectiveness and Resource Allocation 15, 1-19, 2017
492017
Is the impact of childhood influenza vaccination less than expected: a transmission modelling study
F Weidemann, C Remschmidt, S Buda, U Buchholz, B Ultsch, ...
BMC infectious diseases 17, 1-14, 2017
412017
Cost-effectiveness of childhood rotavirus vaccination in Germany
P Aidelsburger, K Grabein, K Böhm, M Dietl, J Wasem, J Koch, B Ultsch, ...
Vaccine, 2014
352014
Epidemiology and cost of seasonal influenza in Germany-a claims data analysis
S Scholz, O Damm, U Schneider, B Ultsch, O Wichmann, W Greiner
BMC Public Health 19, 1-10, 2019
342019
Current and future effects of varicella and herpes zoster vaccination in Germany–Insights from a mathematical model in a country with universal varicella vaccination
J Horn, A Karch, O Damm, ME Kretzschmar, A Siedler, B Ultsch, ...
Human vaccines & immunotherapeutics 12 (7), 1766-1776, 2016
342016
Burden of herpes zoster in adult patients with underlying conditions: analysis of German claims data, 2007–2018
M Batram, J Witte, M Schwarz, J Hain, B Ultsch, M Steinmann, A Bhavsar, ...
Dermatology and therapy 11 (3), 1009-1026, 2021
252021
The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany
S Scholz, F Koerber, K Meszaros, RM Fassbender, B Ultsch, RR Welte, ...
Vaccine 37 (12), 1692-1701, 2019
252019
Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany - a mathematical modelling study
Horn J, Damm O, Greiner W, Hengel H, Kretzschmar ME, Siedler A, Ultsch B ...
BMC Med 16 (1), 3, 2018
24*2018
Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany: Statement of the German …
German Standing Committee on Vaccination (STIKO) at the Robert Koch ...
Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 60 (10), 1162-1179, 2017
192017
Effectiveness, population-level effects, and heath economics of measles and rubella vaccination
O Wichmann, B Ultsch
Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 56, 1260-1269, 2013
18*2013
Standardisierte Kostenberechnungen im deutschen Gesundheitswesen: Bericht der Arbeitsgruppe „Standardkosten “des Ausschusses „ökonomische Evaluation “der dggö
S Scholz, J Biermann-Stallwitz, C Brettschneider, O Damm, A Freytag, ...
Gesundheitsökonomie & Qualitätsmanagement 25 (01), 52-59, 2020
172020
系统目前无法执行此操作,请稍后再试。
文章 1–20